<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486939</url>
  </required_header>
  <id_info>
    <org_study_id>CHS-0214-05</org_study_id>
    <nct_id>NCT02486939</nct_id>
  </id_info>
  <brief_title>A Long Term Safety Extension Study (CHS-0214-05)</brief_title>
  <official_title>An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coherus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Coherus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, Safety Extension Study (OLSES) evaluating the longer-term safety and
      durability of response of subjects who completed 48 weeks of evaluations in the confirmatory
      safety and efficacy studies, CHS 0214-02 or CHS-0214-04, evaluating CHS-0214 in patients with
      rheumatoid arthritis (RA) and plaque psoriasis (PsO), respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Longer-term safety assessed by incidence of adverse events, changes in safety laboratory parameters, vital signs, physical examinations and assessment of immunogenicity</measure>
    <time_frame>Up to 115 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>For subjects with RA, maintenance of at least an ACR20</measure>
    <time_frame>Up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For subjects with PsO, maintenance of at least PASI-50</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">359</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>CHS-0214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHS-0214 50 mg weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHS-0214</intervention_name>
    <description>Open label</description>
    <arm_group_label>CHS-0214</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have completed 48 weeks of evaluations in CHS-0214-02 and, at Week 48, had at least an
             ACR20, or completed 48 weeks of evaluations in CHS-0214-04 and, at Week 48, had at
             least a PASI-50

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Finck, MD</last_name>
    <role>Study Director</role>
    <affiliation>Coherus Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oribe Clinic of Rheumatism and Medicine</name>
      <address>
        <city>Oita</city>
        <state>ÅŒita Prefecture</state>
        <zip>870-0823</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

